Association between metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction subtypes and risk of colorectal cancer: A prospective cohort study
Authors:
- 15 March 2025
- journal article
- Published by Elsevier in Clinics and Research in Hepatology and Gastroenterology
- Vol. 49 (5) , 102573
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Evaluation of long-term benefits and cost-effectiveness of nation-wide colorectal cancer screening strategies in China in 2020–2060: a modelling analysisThe Lancet Regional Health - Western Pacific, 2024
- EASL–EASD–EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)Journal of Hepatology, 2024
- Cardiovascular morbidity and mortality in lean vs. non-lean MASLD: A comprehensive meta-analysisCurrent Problems in Cardiology, 2024
- Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver diseaseJournal of Hepatology, 2024
- Outcomes of subjects who are lean, overweight or obese with nonalcoholic fatty liver disease: A cohort study in ChinaHepatology Communications, 2022
- Epidemiology and risk-stratification of NAFLD-associated HCCJournal of Hepatology, 2021
- Cancer incidence, mortality, and burden in China: a time‐trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020Cancer Communications, 2021
- Associations Between Nonalcoholic Fatty Liver Disease and Cancers in a Large Cohort in ChinaClinical Gastroenterology and Hepatology, 2021
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Insulin, Glucose, Insulin Resistance, and Incident Colorectal Cancer in Male SmokersClinical Gastroenterology and Hepatology, 2006